Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 212 от 240

Активно (без набиране)

A Study of Pulmonary Hypertension Peripheral Limitations

Pulmonary Arterial Hypertension Healthy

The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).

Начало: 02.01.2024 Край: 01.09.2026 Възраст: от 18 г.

United States Mayo Clinic NCT05968859

Активно (без набиране)

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

The goal of this clinical trial is to learn if immune microenvironment modification could improve the effect of chemoradiotherapy for patients with local advanced esophageal squamous cell carcinoma. The main questions it aims to answer are: 1. Does immune microenvironment could be modified by medium dose of three drugs (paclitaxel, cisplatin, 5-FU), PD1 checkpoint inhibitor, probiotics, and thymosin α1？ 2. Does induction and consolidation of PD1 checkpoint inhibitor improve the effect of chemoradiotherapy for patients with esophageal cancer? This is a single arm study. Participants will: 1. Take one cycle of induction chemotherapy (paclitaxel, cisplatin, 5-FU) and immunotherapy (Sintilimab), two cycle of concurrent chemoradiotherapy, one cycle of consolidation chemo-immunotherapy, and then 1 year of immunotherapy. 2. Take probiotics (Clostridium Butyricum) for 1 year and thymosin alpha-1 daily during radiotherapy.

Начало: 21.12.2023 Край: 10.07.2027 Възраст: 18–80 г.

China Fudan University NCT06401447

Активно (без набиране)

Journey of Transformation Curriculum for Native American Youth

Alcohol Drinking Tobacco Use Substance Use Sexual Behavior

The investigators will conduct a waitlist control trial to test the efficacy of the Journey of Transformation-Native Youth Health Leadership Program (JOT) in terms of delaying or reducing tobacco and other substance use and improving sexual health.

Начало: 11.12.2023 Край: 28.02.2027 Възраст: 13–16 г.

United States University of Washington NCT05731713

Активно (без набиране) Фаза 2

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

Myelodysplastic Syndrome Anemia in Myelodysplastic Syndromes

This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia. The study includes a 28-day Screening Period followed by a 16- or 32-week Treatment Period. Participants will be monitored at each cycle for drug tolerance, safety, and hematological response. A response assessment will occur after 16 weeks of study treatment.

Начало: 09.12.2023 Край: 25.05.2026 Възраст: от 18 г.

India Halia Therapeutics, Inc. NCT07052006

Активно (без набиране) Фаза 2

HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

This is an open-label, single-arm, phase 2 study evaluating hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and cadonilimab as conversion therapy for initially unresectable hepatocellular carcinoma (HCC). The primary objective is to assess the conversion rate, defined as the proportion of participants who are deemed amenable to curative-intent treatment by the multidisciplinary team (MDT), including R0 resection, curative ablation, or liver transplantation, after study treatment. Secondary objectives include curative-intent intervention rate, tumor response, survival outcomes, safety, pathological response, and exploratory tissue and blood biomarkers.

Начало: 07.12.2023 Край: 30.06.2028 Възраст: от 18 г.

China Tongji Hospital NCT06187961

Активно (без набиране) Фаза 2

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Clinical Stage I Gastric Cancer AJCC v8 Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage II Gastric Cancer AJCC v8 Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 +6

This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease in patients with gastric or gastroesophageal junction (JEG) cancer that has not spread from where it first started (local) or only has spread to nearby lymph nodes or tissue (locoregional) and has high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The mismatch repair (MMR) system in the body corrects errors made during the copying of DNA and serves as a proofreading function. If this system isn't working correctly, mutations (changes) in DNA occur which can allow the cancer to grow or spread. This is called dMMR (deficient mismatch repair) . MSI-H describes cancer cells that have a high number of mutations within microsatellites. For example, microsatellite testing that shows mutations in 30% or more microsatellites is called microsatellite instability-high (MSI-H). Microsatellites are short, repeated sequences of DNA. There is evidence that MSI-H/ dMMR gastric or GEJ tumors respond well to immunotherapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Chemotherapy drugs such as leucovorin calcium and fluorouracil work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using atezolizumab as immunotherapy with and following chemotherapy versus atezolizumab alone prior to and after surgery may shrink or stabilize the tumor in patients with MSI-H/dMMR localized gastric or GEJ cancer and may increase the length of time after treatment that cancer does not come back or get worse.

Начало: 06.12.2023 Край: 31.10.2027 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT05836584

Активно (без набиране) Фаза 3

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

Nasopharyngeal Carcinoma

A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based chemotherapy after receiving PD-1/PD-L1 monoclonal antibody as the last line of therapy.

Начало: 04.12.2023 Край: 01.11.2026 Възраст: 18–75 г.

China Sichuan Baili Pharmaceutical Co., Ltd. NCT06118333

Активно (без набиране) Фаза 2

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

Mild Cognitive Impairment Due to Alzheimer's Disease Alzheimer's Disease, Early Onset

Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour. The company PRInnovation is developing a new treatment for Alzheimer's disease, called PRI-002. It is thought that PRI-002 can cut the sticked substances back into small pieces. That would reduce the effects of Alzheimer's disease. In the current study the investigators examine whether PRI-002 is safe and effective in participants with mild cognitive impairment (MCI) or mild dementia due to AD.

Начало: 01.12.2023 Край: 30.06.2026 Възраст: 55–80 г.

Czechia, Germany, Italy +3 PRInnovation GmbH NCT06182085

Активно (без набиране) Фаза 1/2

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.

Начало: 17.11.2023 Край: 02.09.2026 Възраст: 18–65 г. Фундаментална наука

Australia, Belgium, Canada +11 Pfizer NCT06137742

Активно (без набиране) Фаза 3

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

Начало: 11.11.2023 Край: 01.12.2032 Възраст: от 18 г. Лечение

Australia, Austria, Brazil +18 BeOne Medicines NCT06073821

Активно (без набиране) Фаза 3

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Systemic Sclerosis Scleroderma

The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

Начало: 08.11.2023 Край: 05.04.2028 Възраст: 18–70 г.

Austria, Belgium, Canada +20 AstraZeneca NCT05925803

Активно (без набиране)

Sickle Cell Children's Exercise Study (SuCCESs)

Sickle Cell Disease

The Sickle Cell Children's Exercise Study (SuCCESs) will explore the feasibility and effects of a moderate intensity strengthening, balance, speed, and agility intervention program in children with sickle cell disease.

Начало: 03.11.2023 Край: 31.12.2026 Възраст: 6–17 г.

United States University of Maryland, Baltimore NCT06074198

Активно (без набиране)

Remote Game-based Exercise Program for Cognitive and Motor Function Improvement

Mild Cognitive Impairment Dementia Cognitive Impairment Memory Loss

As our population ages, more older adults face motor-cognitive declines, increasing their risk of falls and fear of falling. Exercise is an effective way to maintain cognitive function, as supported by recent studies. However, those with poor motor and cognitive abilities often struggle to visit rehabilitation centers, leading to high dropout rates and low adherence to unsupervised programs. A remote exercise program tailored for individuals with cognitive impairments is urgently needed to preserve cognitive function, promote independent living, and reduce related costs. Researchers aim to develop an in-home system for adults with mild cognitive issues or dementia, designed to improve balance and cognition while being remotely supervised through telemedicine.

Начало: 03.11.2023 Край: 30.06.2026 Възраст: от 55 г.

United States University of California, Los Angeles NCT05235113

Активно (без набиране)

Optimal Stent Duration After Ureteroscopy

Ureteral Stent

The purpose of this study is to determine how soon ureteral stents can be safely removed following surgery.

Начало: 01.11.2023 Край: 01.09.2026 Възраст: от 18 г.

Canada, United States Mayo Clinic NCT06045962

Активно (без набиране) Фаза 2

Realizing Effectiveness Across Continents With Hydroxyurea

Sickle Cell Disease Children

REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs.

Начало: 27.10.2023 Край: 04.10.2033 Възраст: 3–10 г.

Angola, Democratic Republic of the Congo, Kenya +1 Children's Hospital Medical Center, Cincinnati NCT06171217

Активно (без набиране)

Effectiveness of the Evaluation and Communication of "Pulmonary Age" as Help for Smoking Cessation

Smoking Cessation

The experimental design is a cluster randomized trial in 2 parallel groups: an intervention group with assessment of the pulmonary age and a control group without. The population studied is patients aged 25 or more, smoking for more than a year, seen in general practice consultation, for any reason. The progress of the study will be composed of an inclusion visit (M0) with a pulmonary age estimation for the intervention group and an measurement of the exhaled carbon monoxide for both groups, then a follow-up visit 6 months after the inclusion (M6) with an exhaled carbon monoxide measure for both groups, and a phone call at 12 months (M12) with a quality of life survey for both groups. The primary outcome is the smoking cessation at 6 months, confirmed by the carbon monoxide exhaled, at a scheduled consultation with the General practitioner (GP).

Начало: 27.10.2023 Край: 30.06.2026 Възраст: от 25 г.

France Assistance Publique - Hôpitaux de Paris NCT04276116

Активно (без набиране)

Digital Therapy for Fatty Liver Disease

Steatohepatitis, Nonalcoholic Nonalcoholic Fatty Liver

This study is a randomised controlled trial of the clinical application of the Fatty Liver Data Analysis and Intervention System (FLDAS) to compare the effectiveness of traditional lifestyle interventions in patients with fatty liver with digital therapies combining software and hardware devices; to validate the effectiveness of digital therapies in patients with fatty liver; and to evaluate the effectiveness of remote lifestyle (diet and exercise) interventions. Researchers conducted a randomised controlled trial to compare the effectiveness of a traditional lifestyle intervention for patients with fatty liver with a remote lifestyle (diet and exercise) intervention combining digital therapy software and hardware devices. When the effectiveness of this programme is validated, it could help clinicians improve the efficiency of lifestyle interventions for patients with fatty liver and address the growing need for primary care for patients with fatty liver as an innovative approach to disease intervention.

Начало: 26.10.2023 Край: 31.12.2026 Възраст: 18–65 г.

China Xinhua Hospital, Shanghai Jiao Tong University School o NCT07007741

Активно (без набиране) Фаза 2

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)

Начало: 25.10.2023 Край: 01.09.2026 Възраст: 18–75 г.

India, Puerto Rico, United States Corcept Therapeutics NCT06108219

Активно (без набиране) Фаза 2

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Locally Advanced Extraskeletal Myxoid Chondrosarcoma Locally Advanced Leiomyosarcoma Locally Advanced Liposarcoma Locally Advanced Undifferentiated Pleomorphic Sarcoma +6

This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Adding cabozantinib to the combination of ipilimumab and nivolumab may be better in stopping or slowing the growth of tumor compared to ipilimumab and nivolumab alone in patients with advanced soft tissue sarcoma.

Начало: 25.10.2023 Край: 15.05.2026 Възраст: от 18 г.

Canada, United States National Cancer Institute LAO NCT05836571

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Начало: 25.10.2023 Край: 27.12.2027 Възраст: от 21 г. Лечение

Argentina, Australia, Austria +32 Bristol-Myers Squibb NCT06025578

1 … 210 211 212 213 214 … 240